Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Coalition’s Cost-Cutting Pledge Needs Five-Year Target – Orszag

Executive Summary

The Obama administration wants to wait no more than five years for private health care stakeholders to make good on their pledge to collectively reduce health care cost growth by 1.5 percentage points annually, according to recent comments by White House Office of Management and Budget Director Peter Orszag

You may also be interested in...



Obama Medicaid Rebate Provisions Make Way Into Finance Cmte. Options

The Senate Finance Committee is looking to the pharmaceutical industry to contribute to paying for health care reform in the form of adjustments to Medicaid rebates and the introduction of means testing in Medicare Part D

Bending The Cost Curve: Obama Presses For Specifics On Coalition Pledge

The White House is expecting a private sector healthcare coalition - including the pharmaceutical industry - to produce details in early June on a pledge to help reduce the annual health care spending growth rate by 1.5 percentage points over the next 10 years

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS051119

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel